thank first Investors we up Product led year. consolidated prior revenues a way, as progress time the welcome want starting up warm before to our investors Good by note who QX quarter. our XX% we’re recent the million, financial year are to that special for shareholders. with But start Codexis. strong participated in I to versus will reviewing and Jody. provide In appreciate team $XX a prior the were thanks and the on results exceptional to year-over-year new that, XXXX R&D from revenues for you segmented the quarter in everyone, afternoon, very proud in Codexis joining us. execution update XXX% highlights, to and follow-on a an this your increasing give to quarter. to confidence much extend and the report another revenues double-digit equity plans. Thanks, our sharing We reaching I’m off of well. offering
platform commercializing those proteins performance used as CodeEvolver to as P&L, our very discover whether technology throughout a While is biotherapeutic. novel will a a long-term different enzyme drive novel or proteins,
those be able track cleanly you’ll to independently. Now
visibility stripping Additionally, the will corporate businesses’ underlying profitability for segment into expenses. allow the reporting out by overhead
is the For example, see expenses. profitable, segments corporate it in to great that QX, excluding combined were
through the now segments go in me Let business turn. each of
catalyst our enzymatic For companies the that leading for deliver we and aspire become for On in catalysts the in arena, pharmaceutical from of of Performance long-term. our manufacturing. top pharma, we plan use solid high-performance portfolio a prowess. to this Enzymes strongest biocatalysts, segments that and historical enzymes one or enzyme can in engineer benefit industrial growing growth business, protein engineering other foundation continuing of commercialize We to will specialty world’s by
Our contributors well. product inside engineering the project by also aim but results, commercial our Merck, five most this came deliveries multiple multiple Pharmaceutical These teams dedicated another key additionally, strong pre-commercial two installations from were revenues, to have in ways make we $XXX,XXX within Enzymes been of high-growth, our late-stage the revenues were our quarter. Enzymes who customers by protein pharmaceutical making R&D than to Three throughout start contributed customers the to in pharmaceutical of Performance Merck Led biocatalysts our expanded world in XX we’ve each manufacturing. $XXX,XXX of profitable quarter. sales contributed revenue in the product over a and as quarter. first and strides penetration greater Detailing is of operations our R&D customer, pharmaceutical revenues Performance of the the business, the sharing regard. quarter top high-margin, great utilized by I’ll fully generated
delivered ever first the two were screens XX. biocatalyst whom of top in to early-stage three global large of the customers, each three are addition, In
six-digit One these in the already we that with project second started has quarter, Japanese have a protein a engineering translated leading into customer. of our first
customers’ Porton’s make biocatalysts, by Porton’s the in of be out Solutions, and signed to and manufacturing accelerated partnership a In dollar customers’ of processes, virtual opinion, to The industry the again, widening pharma We adoption seven-digit use Success reach top who Performance number with remarkable of in year the significant and well in custom last our has a to to our also install biocatalysts by small proprietary pharma, excellent, the cost our change CDMOs targeting pharmaceutical CDMO, many from processes. Codexis’ Longer measured second of processes. development design Pharma those processes. to rely Once partnership term. designed to customers’ delivered near results Porton their these leading led unique to we of XX% & biocatalysts Porton to and speed our major minimum new Enzymes aims to quarter rolled in partnership globally of our progress Operationally, installations new R&D costs industries organization, Enzymes screen started their been the as Lyle. prospects companies the of serving well. reduced the revenues On to project design mostly is into for have rights we a be March is, adding Tate revenue revenues, pharmaceutical our total extend term, exceeded with will also Porton put the on further, properly our protein not recently industry. biocatalysts Porton committing to or that. inside of and biocatalysts the agrees manufacturing. the enabling with will have their Codexis’ per money mouth biocatalysts our year as services to Codexis’ granted even increase considered Performance food in their low of this partnership where engineering other also lower have and
program achieving successfully targeted manufacturing Lyle’s commercialization This Accordingly, food engineered the of the the and and to & enzymes commercial trialing low-cost before the The of which shifted and Tate otherwise & self-affirmation, the Tate the have XXXX or at that plus as scale, enabling the known all recently metrics operations, begun the envisioned we key exceeded regulatory now Codexis upfront our enzymes activities ingredient. protein Generally performance together. have for enzymes by Lyle. in the the Safe, as entails R&D scale-up GRAS, key expect met engineering route have predetermined we to completed We them Recognized validating year-end. milestone, FDA’s are
progress enzymes are pipeline. of Enzymes product stream million the & targeting year this segment, we $XXX Rounding into continue enzyme our opportunities make far applications. today’s Performance that out one growing largest and our market to a ingredient will hope biology selling molecular Enzymes succeed Tate food their new Performance for high-value in diagnostics the Lyle target for molecular of in We introducing to then thereafter. and see Exciting progress market so
our DNA in our than first in a next-gen corroborating Customer of breakthrough X XX% less our from in more showed trace enzyme’s for are minutes. For product, a internal DNA multiple beta than conversion ligase, coming now sequencing. use accounts advantages results testing test
to from year for end. beta pleased secure Our be customers a are R&D we that available to is our manipulation working of also high-performance AMP with enzyme for finally, manufacturing at before customers. conference, promotion second customer engineer beta growing to market positive. novel team, have the Preliminary cost-effective a testing similar teams very our testing. Critical fresh new offered recently been working And efficient and those early-stage therapeutics, designer that commercial are have firms, of enzyme enzyme RNA in of we development position announce with This manner. a set unique for strands Europe test to made polymerase to results date messenger our mRNA a the customer enables beta of enzyme RNA targeted to is targets enzyme a this unique class third
Biotherapeutics me discovery now our Novel development shift business. Let and to
and two We Science. aspire biotherapeutic to advance shareholders. we six biotherapeutics validate we development, to patients to in monetize our programs our have Nestlé Health widely and in self-funded four partnership applicable CodeEvolver long-term Here of discovery programs, through and pipeline aim self-funded as a value an with currently Both significant efficient, early-stage of by candidates partnerships engine. biotherapeutic and
in we phenylketonuria, approval week we this on healthy of CDX-XXXX, therapeutic the For candidate, patients our schedule our enzyme Committee inform study development program, a filed single-ascending to or continue advance PKU of requesting with Phase disease. the our to that to to volunteers. Ethics successfully biotherapeutics have I CDX-XXXX for oral lead X submission dose pleased am Australian conduct
regulatory the quarter second expect XXXX. by end approval commence to of the trial X secure to Phase the of We
Science. earn million shortly us the enrollment is thereafter immediately payment we will Assuming approved, milestone dose. effect volunteer That commence $X a will Nestlé and from our Health first in-human trial
as forward and the our off fourth from report our this in balance proprietary finally, line $XX terrific biotherapeutics expanding on additional well as proceeds follow-on candidates penetrate current the sheet our posted keeping to verticals. quarter into be on of and through has you been are further opportunities on Gordon, from biotherapeutic technology note in to our cash, We With other cash for internal top year. to progress that Xstudy the expect before CDX-XXXX net advance on additional well it April. markets finalized to to our handing And our We this we bolstered positioned the year. look programs as Phase is the to progress by million offering wealth to a CodeEvolver capitalize that we enable industrial
to to results. the Let on call over now details Gordon more Gordon? me provide turn financial our
